Mounjaro A1C requirements and what they mean for your eligibility

Picture this: your HbA1c result arrives and you're not sure whether it helps or hinders

You open a letter or an NHS app notification. Your HbA1c is 48 mmol/mol (just into the diabetic range) or perhaps it's 42, sitting in the prediabetes band. Your BMI is above 30. You've read that Mounjaro is available for weight management, but also that it's used in diabetes, and you're unsure which category you fall into, or whether your result makes you ineligible.

This is one of the questions our prescribers field regularly. The reassuring reality is that a high or borderline HbA1c rarely closes a door. More often it provides additional clinical context that supports eligibility. Mounjaro (tirzepatide) is licensed in the UK for two distinct purposes, and the A1C implications differ between them. Understanding which licence is relevant to you is the first step, and our Mounjaro overview sets out both licences clearly if you'd like the broader picture first.

What the weight-management licence actually requires, and where A1C fits in

The Mounjaro weight-management licence, granted by the MHRA and evaluated by NICE in TA1026, does not specify a required HbA1c level. The core eligibility criteria are BMI-based: adults with a BMI of 30 or above, or 27 and above if at least one weight-related health condition is present. Those conditions include type 2 diabetes, prediabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea, and cardiovascular disease, among others. Your HbA1c result can serve as clinical evidence of one of those conditions, which may actually strengthen your case for treatment rather than weaken it.

If your HbA1c indicates prediabetes (42–47 mmol/mol) or type 2 diabetes (48 mmol/mol and above) and your BMI meets the threshold, both criteria can be satisfied together. If your blood sugar is entirely normal, eligibility still holds as long as the BMI requirement is met, A1C is not a gatekeeping figure for the weight-management route. The full eligibility picture, including how BMI thresholds are calculated, is covered on our Mounjaro BMI requirement page.

NICE TA1026 also notes that lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, where the threshold drops by 2.5 kg/m².

When a high HbA1c is clinically important: the diabetes licence and NHS criteria

Mounjaro also holds a separate UK licence for type 2 diabetes management, where HbA1c is far more central. In a diabetes context, a prescriber will look at your HbA1c alongside other factors (existing medicines, kidney function, cardiovascular risk) when considering tirzepatide as part of your diabetes care. That is a clinical conversation for your GP or diabetologist rather than an online pharmacy. If you have type 2 diabetes and are primarily seeking weight management, both licences can be relevant simultaneously; a prescriber will determine which clinical pathway fits.

For NHS access under NICE TA1026, having type 2 diabetes counts as one of the qualifying comorbidities in the phased rollout. The current phase (from June 2025) requires a BMI of 40 or above with four or more of the five listed conditions. Type 2 diabetes is on that list, so a confirmed diagnosis supported by HbA1c evidence can contribute toward meeting the threshold. Private access through a regulated pharmacy like nume (sorry, like nume) follows the licensed criteria directly, without the NHS phase restrictions. If you'd like to understand what the requirements for Mounjaro are, including how NHS and private routes compare, that page brings together the key criteria in one place.

What happens at a nume consultation when your A1C is elevated

When you complete a free consultation with nume, our prescribers review your full health profile. If you mention a recent HbA1c result (or share that you have prediabetes or type 2 diabetes) that information is factored into the clinical assessment alongside your BMI, current medicines, and any other relevant conditions, and you can read through the Mounjaro requirements we apply at that stage if you'd like to know what our prescribers are looking for. A prescriber, not an algorithm, reads your answers on the same day.

If you're already taking Mounjaro through another provider and transferring to us, we ask for evidence of your current dose and clinical history. Dose increases require clinical review each time. For practical day-to-day use, our prescribers often remind patients to keep their pen in the fridge door where they'll notice it, the weekly injection routine is easier to maintain when it's visible rather than tucked away.

The cost of treatment is worth understanding before you start. The Eli Lilly price increase in September 2025 changed the UK market significantly, and our treatment page shows current pricing clearly. If you'd like to check whether your specific situation meets the criteria, the most direct route is a free consultation with our clinical team. There are more detailed eligibility checks available if you want to work through your situation before booking.